ARTICLE: Broadly neutralizing antibodies target the coronavirus fusion peptide

The Pandemic Is Driving Innovative Microfluidic Disease Detection

Berkeley Lights and Bayer Announce Agreement to Spur Discovery of Next-Generation Traits

Mapping the Future of Cell Culture and Cell Line Development

Meet The Collaboration Solving Some Of Antibody Discovery’s Toughest Problems

Leveraging optofluidics to make therapeutic antibody discovery easier

Researchers pivot from COVID-19 response to preventing future pandemics

Military programs aiming to end pandemics forever

From Discovery To Delivery: Addressing Challenges in Cell Therapy

Biotech’s Brave New World: Bay Area startups band together to ramp up coronavirus research and testing

JP Morgan Healthcare Conference 2021, Day Two:Qiagen, Invitae, Agilent, Sema4, More

Finding the Best Cell for the Job

Pinpointing Bioprocess Development Success

Big Tech Is Under Pressure. Here’s Where to Find Growth

Berkeley Lights Helps Researchers Connect Genomic, Functional Characteristics of Cells

Soaring Biomedical IPOs Raise Questions About Money Left on the Table

Berkeley Lights Will Receive IPO of the Year Award at SynBioBeta 2020

Optofluidics Technology Accelerates Discovery of COVID-19 Treatments